Fosun, which holds a 57.86% stake in Gland Pharma, according to exchange data, did not immediately respond to Reuters' request for comment. Gland Pharma declined to comment.
(Reporting by Nandan Mandayam in Bengaluru; Editing by Savio D'Souza)
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.13 CNY | +1.45% | -6.24% | -7.59% |
Mar. 27 | Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates | MT |
Mar. 27 | Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. | CI |
BENGALURU (Reuters) - China's Shanghai Fosun Pharmaceutical Group Co Ltd is considering a sale of Indian drugmaker Gland Pharma Ltd, which has a market value of $3.5 billion, Bloomberg reported, citing people familiar with the matter.
Fosun, which holds a 57.86% stake in Gland Pharma, according to exchange data, did not immediately respond to Reuters' request for comment. Gland Pharma declined to comment.
(Reporting by Nandan Mandayam in Bengaluru; Editing by Savio D'Souza)
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,845 INR | +1.36% | +5.26% | 3.65B | ||
23.13 CNY | +1.45% | -6.24% | 7.69B | ||
1st Jan change | Capi. | |
---|---|---|
-7.59% | 7.69B | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |